{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:31:48Z","timestamp":1787668308333,"version":"build-2736575974"},"reference-count":31,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>\n                    Carbapenem-resistant\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    (CRKP) has become a serious challenge for clinical treatment and public health. We found that both KPC-2-producing\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    (KPC-KP) and NDM-1-producing\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    (NDM-KP) are epidemic in a teaching hospital in Northeast China. The main aim of the present study was to compare antimicrobial susceptibility differences between KPC-KP and NDM-KP and elucidate complex resistant genotypes of the KPC-KP and NDM-KP by PCR and sequencing. Among 82 CRKP isolated between January 2015 and December 2016, 59 isolates were KPC-KP and 23 isolates were NDM-KP. All 59 KPC-KP had no susceptibility to gentamicin, tobramycin, levofloxacin, and ciprofloxacin, had very low susceptibility to amikacin (3.39%) and fosfomycin (8.47%), whereas the susceptibility of NDM-KP to the above antibiotics was 21.74%, 13.04%, 17.39%, 17.39%, 69.57%, and 73.91%, respectively. Although the susceptibility of NDM-KP to tigecycline (95.65%) and polymyxin B (73.91%) was higher than that of KPC-KP (84.75% and 69.49%, respectively), the difference was not statistically significant. The MIC\n                    <jats:sub>90<\/jats:sub>\n                    of KPC-KP and NDM-KP to aztreonam-avibactam were 4 and 2\u2009\u03bcg\/mL, respectively. All 82 CRKP carried 2 or 3 Extended Spectrum Beta-Lactamase (ESBL) genes, and 79\/82 CRKP carried the AmpC gene\n                    <jats:italic toggle=\"yes\">\n                      bla\n                      <jats:sub>FOX<\/jats:sub>\n                    <\/jats:italic>\n                    . The aminoglycoside resistance gene\n                    <jats:italic toggle=\"yes\">rmtB<\/jats:italic>\n                    was detected in 96.61% of KPC-KP and in 21.74% of NDM-KP. It seems that KPC-KP was more resistant to antibiotics than NDM-KP in this study, so that available therapeutic regimens against KPC-KP are very limited. Aztreonam-avibactam may be a promising and valuable option against both KPC-KP and NDM-KP.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2018.0398","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T10:48:25Z","timestamp":1566384505000},"page":"94-99","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["<i>In Vitro<\/i>\n                    Antimicrobial Susceptibility Differences Between Carbapenem-Resistant KPC-2-Producing and NDM-1-Producing\n                    <i>Klebsiella pneumoniae<\/i>\n                    in a Teaching Hospital in Northeast China"],"prefix":"10.1177","volume":"26","author":[{"given":"Lin","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2012.10.012"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.medmal.2013.11.007","article-title":"Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge","volume":"44","author":"Nordmann P.","year":"2014","unstructured":"Nordmann P. 2014. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. Med. Mal. Infect. 44:51\u201356.","journal-title":"Med. Mal. Infect"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00895"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00001-07"},{"key":"e_1_3_4_7_2","first-page":"3219","volume-title":"Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant. Proc.","author":"Mouloudi E.","unstructured":"Mouloudi E., , Massa E., , Piperidou M., , Papadopoulos S., , Iosifidis E., , Roilides I., , Theodoridou T., , Kydona C., , Fouzas I., , Imvrios G., , Papanikolaou V., , and Gritsi-Gerogianni N.. 2014. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant. Proc., 46:3219\u20133221."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2015.06.003"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jinf.2014.10.001","article-title":"Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae","volume":"70","author":"Chua N.G.","year":"2015","unstructured":"Chua N.G., , Zhou Y.P, , Tan T.T, , Lingegowda P.B, , Lee W., , Lim T.P, , Teo J., , Cai Y., , and Kwa A.L.. 2015. Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae. J. Infect. 70:309\u2013311.","journal-title":"J. Infect"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/etm.2017.4046","article-title":"Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae","volume":"13","author":"Liao Y.","year":"2017","unstructured":"Liao Y., , Hu G.H, , Xu Y.F, , Che J.P, , Luo M., , Zhang H.M, , Peng B., , Yao X.D, , Zheng J.H, , and Liu M.. 2017. Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae. Exp. Ther. Med. 13:1003\u20131010.","journal-title":"Exp. Ther. Med"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_4_12_2","first-page":"123","volume":"123","author":"Sun K.","year":"2015","unstructured":"Sun K., , Chen X., , Li C., , Yu Z., , Zhou Q., , and Yan Y.. 2015. Clonal dissemination of multilocus sequence type 11 Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in a Chinese teaching hospital. APMIS. 123:123\u2013127.","journal-title":"Clonal dissemination of multilocus sequence type 11 Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in a Chinese teaching hospital. APMIS"},{"key":"e_1_3_4_13_2","volume-title":"PLoS One 10:e0119571","author":"Jin Y.","year":"2015","unstructured":"Jin Y., , Shao C., , Li J., , Fan H., , Bai Y., , and Wang Y.. 2015. Outbreak of multidrug resistant NDM-1-producing Klebsiella pneumoniae from a neonatal unit in Shandong Province, China. PLoS One 10:e0119571."},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/jac\/dkr184","article-title":"Rapid detection of the blaNDM-1 gene by real-time PCR","volume":"66","author":"Ong D.C.","year":"2011","unstructured":"Ong D.C., , Koh T.H, , Syahidah N., , Krishnan P., , and Tan T.Y.. 2011. Rapid detection of the blaNDM-1 gene by real-time PCR. J. Antimicrob. Chemother. 66:1647\u20131649.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/JCM.01943-07","article-title":"Molecular epidemiology of extended-spectrum \u03b2-lactamases among Escherichia coli isolates collected in a Swedish Hospital and its Associated Health Care Facilities from 2001 to 2006","volume":"46","author":"Fang H.","year":"2008","unstructured":"Fang H., , Ataker F., , Hedin G., , and Dornbusch K.. 2008. Molecular epidemiology of extended-spectrum \u03b2-lactamases among Escherichia coli isolates collected in a Swedish Hospital and its Associated Health Care Facilities from 2001 to 2006. J. Clin. Microbiol. 46:707\u2013712.","journal-title":"J. Clin. Microbiol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.6.2153-2162.2002"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"e47636","DOI":"10.1371\/journal.pone.0047636","article-title":"Prevalence of plasmid-mediated quinolone resistance and aminoglycoside resistance determinants among carbapeneme non-susceptible Enterobacter cloacae","volume":"7","author":"Huang S.","year":"2012","unstructured":"Huang S., , Dai W., , Sun S., , Zhang X., , and Zhang L.. 2012. Prevalence of plasmid-mediated quinolone resistance and aminoglycoside resistance determinants among carbapeneme non-susceptible Enterobacter cloacae. PLoS One, 7:e47636.","journal-title":"PLoS One"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/518605"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2009.0868"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.8.4178-4182.2005"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/527442"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01086-10","article-title":"In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development","volume":"55","author":"Souli M.","year":"2011","unstructured":"Souli M., , Galani I., , Boukovalas S., , Gourgoulis M.G, , Chryssouli Z., , Kanellakopoulou K., , Panagea T., , and Giamarellou H.. 2011. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55:2395\u20132397.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2004.05.005"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/jac\/dkr563","article-title":"Rapid detection of carbapenemase genes by multiplex real-time PCR","volume":"67","author":"Monteiro J.","year":"2012","unstructured":"Monteiro J., , Widen R.H, , Pignatari A.C, , Kubasek C., , and Silbert S.. 2012. Rapid detection of carbapenemase genes by multiplex real-time PCR. J. Antimicrob. Chemother. 67:906\u2013909.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06268-11"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann D.E.","year":"2012","unstructured":"Ehmann D.E., , Jahic H., , Ross P.L, , Gu R.F, , Hu J., , Kern G., , Wakup G.K, , and Fisher S.L.. 2012. Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor. Proc. Natl. Acad. Sci. U S A. 109:11663\u201311668.","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D-lactamases","volume":"288","author":"Ehmann D.E.","year":"2013","unstructured":"Ehmann D.E., , Jahic H., , Ross P.L, , Gu R.F, , Hu J., , Durand-R\u00e9ville T.F, , Lahiri S., , Thresher J., , Livchak S., , Gao N., , Palmer T., , Walkup G.K, , and Fisher S.L.. 2013. Kinetics of avibactam inhibition against class A, C, and D-lactamases. J. Biol. Chem. 288:27960\u201327971.","journal-title":"J. Biol. Chem"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dkw239","article-title":"Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections","volume":"71","author":"Falcone M.","year":"2016","unstructured":"Falcone M., , and Paterson D.. 2016. Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections. J. Antimicrob. Chemother. 71:2713\u20132722.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"e00472","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky J.A.","year":"2017","unstructured":"Karlowsky J.A., , Kazmierczak K.M, , de Jonge B.L.M, , Hackel M.A, , Sahm D.F, , and Bradford P.A.. 2017. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob. Agents Chemother. 61:pii: e00472-17.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_31_2","first-page":"e01856","article-title":"Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates","volume":"62","author":"Sader H.S.","year":"2017","unstructured":"Sader H.S., , Mendes R.E, , Pfaller M.A, , Shortridge D., , Flamm R.K, , and Castanheira M.. 2017. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob. Agents Chemother. 62:pii: e01856-17.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1128\/AAC.02123-13","article-title":"In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China","volume":"58","author":"Wang X.","year":"2014","unstructured":"Wang X., , Zhang F., , Zhao C., , Wang Z., , Nichols W.W, , Testa R., , Li H., , Chen H., , He W., , Wang Q., , and Wang H.. 2014. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob. Agents Chemother. 58:1774\u20131778.","journal-title":"Antimicrob. Agents Chemother"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2018.0398","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:34:27Z","timestamp":1777667667000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2018.0398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1089\/mdr.2018.0398"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2018.0398","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}